<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Cancer Commun (Lond)</journal-id>
<journal-id journal-id-type="iso-abbrev">Cancer Commun (Lond)</journal-id>
<journal-title-group>
<journal-title>Cancer Communications</journal-title>
</journal-title-group>
<issn pub-type="epub">2523-3548</issn>
<publisher>
<publisher-name>BioMed Central</publisher-name>
<publisher-loc>London</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">31753025</article-id>
<article-id pub-id-type="pmc">6873554</article-id>
<article-id pub-id-type="publisher-id">421</article-id>
<article-id pub-id-type="doi">10.1186/s40880-019-0421-5</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Review</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Post-translational modification of Parkin and its research progress in cancer</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Ding</surname>
<given-names>Dan</given-names>
</name>
<address>
<email>17852419591@163.com</email>
</address>
<xref ref-type="aff" rid="Aff1">1</xref>
<xref ref-type="aff" rid="Aff2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ao</surname>
<given-names>Xiang</given-names>
</name>
<address>
<email>xiangao2016@163.com</email>
</address>
<xref ref-type="aff" rid="Aff1">1</xref>
<xref ref-type="aff" rid="Aff2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Liu</surname>
<given-names>Ying</given-names>
</name>
<address>
<email>liuying_hero@163.com</email>
</address>
<xref ref-type="aff" rid="Aff1">1</xref>
<xref ref-type="aff" rid="Aff2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wang</surname>
<given-names>Yuan-Yong</given-names>
</name>
<address>
<email>wangyy921016@163.com</email>
</address>
<xref ref-type="aff" rid="Aff1">1</xref>
<xref ref-type="aff" rid="Aff3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Fa</surname>
<given-names>Hong-Ge</given-names>
</name>
<address>
<email>fa_hongge@hotmail.com</email>
</address>
<xref ref-type="aff" rid="Aff1">1</xref>
<xref ref-type="aff" rid="Aff2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wang</surname>
<given-names>Meng-Yu</given-names>
</name>
<address>
<email>2410231246@qq.com</email>
</address>
<xref ref-type="aff" rid="Aff1">1</xref>
<xref ref-type="aff" rid="Aff2">2</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>He</surname>
<given-names>Yu-Qi</given-names>
</name>
<address>
<email>endohe@163.com</email>
</address>
<xref ref-type="aff" rid="Aff4">4</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Wang</surname>
<given-names>Jian-Xun</given-names>
</name>
<address>
<email>wangjx@qdu.edu.cn</email>
</address>
<xref ref-type="aff" rid="Aff1">1</xref>
<xref ref-type="aff" rid="Aff2">2</xref>
</contrib>
<aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0455 0905</institution-id><institution-id institution-id-type="GRID">grid.410645.2</institution-id><institution>School of Basic Medical Sciences, </institution><institution>Qingdao University, </institution></institution-wrap>No. 38 Dengzhou Road, Shibei District, Qingdao, 266000 Shandong P. R. China </aff>
<aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0455 0905</institution-id><institution-id institution-id-type="GRID">grid.410645.2</institution-id><institution>Center for Regenerative Medicine, Institute for Translational Medicine, College of Medicine, </institution><institution>Qingdao University, </institution></institution-wrap>Qingdao, 266000 Shandong P. R. China </aff>
<aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="GRID">grid.412521.1</institution-id><institution>Department of Thoracic Surgery, </institution><institution>Affiliated Hospital of Qingdao University, </institution></institution-wrap>Qingdao, 266000 Shandong P. R. China </aff>
<aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1761 8894</institution-id><institution-id institution-id-type="GRID">grid.414252.4</institution-id><institution>Department of Gastroenterology, </institution><institution>The Seventh Medical Center of PLA General Hospital, </institution></institution-wrap>Beijing, 100700 China </aff>
</contrib-group>
<pub-date pub-type="epub">
<day>21</day>
<month>11</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>21</day>
<month>11</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="collection">
<year>2019</year>
</pub-date>
<volume>39</volume>
<elocation-id>77</elocation-id>
<history>
<date date-type="received">
<day>12</day>
<month>8</month>
<year>2019</year>
</date>
<date date-type="accepted">
<day>7</day>
<month>11</month>
<year>2019</year>
</date>
</history>
<permissions>
<copyright-statement>© The Author(s) 2019</copyright-statement>
<license license-type="OpenAccess">
<license-p><bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.</license-p>
</license>
</permissions>
<abstract id="Abs1">
<p id="Par1">Clinical practice has shown that <italic>Parkin</italic> is the major causative gene found in an autosomal recessive juvenile parkinsonism (AR-JP) via <italic>Parkin</italic> mutations and that the Parkin protein is the core expression product of the <italic>Parkin</italic> gene, which itself belongs to an E3 ubiquitin ligase. Since the discovery of the <italic>Parkin</italic> gene in the late 1990s, researchers in many countries have begun extensive research on this gene and found that in addition to AR-JP, the <italic>Parkin</italic> gene is associated with many diseases, including type 2 diabetes, leprosy, Alzheimer’s, autism, and cancer. Recent studies have found that the loss or dysfunction of <italic>Parkin</italic> has a certain relationship with tumorigenesis. In general, the <italic>Parkin</italic> gene, a well-established tumor suppressor, is deficient and mutated in a variety of malignancies. Parkin overexpression inhibits tumor cell growth and promotes apoptosis. However, the functions of <italic>Parkin</italic> in tumorigenesis and its regulatory mechanisms are still not fully understood. This article describes the structure, functions, and post-translational modifications of Parkin, and summarizes the recent advances in the tumor suppressive function of Parkin and its underlying mechanisms.</p>
</abstract>
<kwd-group xml:lang="en">
<title>Keywords</title>
<kwd>
<italic>Parkin</italic>
</kwd>
<kwd>E3 ubiquitin ligase</kwd>
<kwd>Cancer</kwd>
<kwd>Post-translational modification</kwd>
<kwd>Parkin/PTEN-induced kinase 1 (PINK1)</kwd>
<kwd>NIP3-like protein X</kwd>
<kwd>Ubiquitination</kwd>
<kwd>Sumoylation</kwd>
<kwd>Neddylation</kwd>
<kwd>Phosphorylation</kwd>
</kwd-group>
<funding-group>
<award-group>
<funding-source>
<institution-wrap>
<institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001809</institution-id>
<institution>National Natural Science Foundation of China</institution>
</institution-wrap>
</funding-source>
<award-id>81622005</award-id>
<principal-award-recipient>
<name>
<surname>Wang</surname>
<given-names>Jian-Xun</given-names>
</name>
</principal-award-recipient>
</award-group>
</funding-group>
<funding-group>
<award-group>
<funding-source>
<institution>Beijing National Science Foundation</institution>
</funding-source>
<award-id>7172213</award-id>
<principal-award-recipient>
<name>
<surname>He</surname>
<given-names>Yu-Qi</given-names>
</name>
</principal-award-recipient>
</award-group>
</funding-group>
<custom-meta-group>
<custom-meta>
<meta-name>issue-copyright-statement</meta-name>
<meta-value>© The Author(s) 2019</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="Sec1">
<title>Background</title>
<p id="Par35"><italic>Parkin</italic> gene, also called <italic>PARK2</italic>, is located on chromosome 6q25.2-q27, contains 12 exons, and has a length of about 1.5 Mb [<xref ref-type="bibr" rid="CR1">1</xref>]. It is widely expressed in various tissues and is mainly found in the brain and muscles [<xref ref-type="bibr" rid="CR2">2</xref>]. Since 1998, Kitada et al. [<xref ref-type="bibr" rid="CR3">3</xref>] were the first to discover the <italic>Parkin</italic> gene mutation in a Japanese family diagnosed with Parkinson. To date, many studies have confirmed that <italic>Parkin</italic> has very broad roles, in addition to Parkinson’s disease, and is also associated with many diseases, such as type 2 diabetes, Alzheimer’s disease, multiple sclerosis [<xref ref-type="bibr" rid="CR3">3</xref>–<xref ref-type="bibr" rid="CR6">6</xref>]. There is a certain correlation between <italic>Parkin</italic> and the occurrence and development of tumors according to genetic studies of many cancer patients. Many studies have shown that the in vivo loss of chromosomal region fragments is associated with malignant tumors, such as p53, Rb fragments and fragile sites [<xref ref-type="bibr" rid="CR2">2</xref>]. The <italic>Parkin</italic> gene is located near the fragile site FRA6E [<xref ref-type="bibr" rid="CR3">3</xref>]. FRA6E is located in an unstable region on chromosome 6q26, which is susceptible to mutate under external stimuli and then promotes tumor formation in normal cells [<xref ref-type="bibr" rid="CR3">3</xref>]. <italic>Parkin</italic> is also a class of molecules that exhibits high variability under different signal induction. Various stimuli can modulate Parkin’s activities through different post-translational modifications [<xref ref-type="bibr" rid="CR7">7</xref>] which play a very important role in life activities. Through the post-translational modification, the structure of the protein becomes more complicated, the function is enhanced, the regulation is more refined, and the effect is more distinctive [<xref ref-type="bibr" rid="CR8">8</xref>]. Recent studies have demonstrated that the expression level of <italic>Parkin</italic> is low in cancers and its dysfunctions or loss has certain relationships with many cancers [<xref ref-type="bibr" rid="CR4">4</xref>]. Therefore, an in-depth study of <italic>Parkin</italic> to clarify its connection with cancers will help provide new drug targets and strategies for cancer treatment.</p>
</sec>
<sec id="Sec2">
<title>Overview: structure, regulation, and functions of Parkin</title>
<sec id="Sec3">
<title>Structural domains of Parkin</title>
<p id="Par36">The <italic>Parkin</italic> gene encodes 465 amino acids to form a protein with a molecular weight of about 52 kDa, namely the Parkin protein [<xref ref-type="bibr" rid="CR3">3</xref>]. Parkin is a multi-domain protein, and its C-terminus consists of the ring structure (RING1 and RING2) on both sides and the in-between RING (IBR) in the middle to form the RING1-IBR-RING2 structure [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR10">10</xref>]. In the N-terminal ubiquitin-like domain (UBL), there are 76 amino acids homologous to ubiquitin, which is a ubiquitin-like structural region with a typical ubiquitin folding [<xref ref-type="bibr" rid="CR3">3</xref>], so Parkin protein is considered to be involved in the activities of ubiquitin–proteasome system (UPS) as E3 ubiquitin ligase [<xref ref-type="bibr" rid="CR11">11</xref>] (Fig. <xref ref-type="fig" rid="Fig1">1</xref>a, b).<fig id="Fig1"><label>Fig. 1</label><caption><p>The two-dimensional structure and three-dimensional structure of human Parkin. <bold>a</bold> The two-dimensional structure of the Parkin protein, the letters in the column indicate the domain. <bold>b</bold> Three-dimensional structure of Parkin protein, based on the datasets in cBioPortal (<ext-link ext-link-type="uri" xlink:href="http://www.cbioportal.org">http://www.cbioportal.org</ext-link>). <italic>UBL</italic> ubiquitin-like domain, <italic>RING</italic> loop finger domain, <italic>IBR</italic> in-between RING, cysteine-rich domain, <italic>REP</italic> repressor element of RING</p></caption><graphic id="MO1" xlink:href="40880_2019_421_Fig1_HTML"></graphic></fig>
</p>
</sec>
<sec id="Sec4">
<title>Functions of Parkin</title>
<sec id="Sec5">
<title>Parkin has E3 ubiquitin ligase activity</title>
<p id="Par37">Ubiquitination refers to the process in which ubiquitin molecules classify proteins in cells under the action of E1, E2 and E3 enzymes, select target protein molecules, and specifically modify target proteins [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR8">8</xref>]. In addition to degradation by the proteasome, ubiquitination can also act as a signal for autophagy degradation by lysosomes and alter the activity or location of the substrate protein [<xref ref-type="bibr" rid="CR12">12</xref>]. As an E3 ligase, Parkin can ubiquitinate the substrate delivered by E2 binding enzyme and further deliver the ubiquitinated substrate to the proteasome, which is degraded into small molecules by proteasome action for recycling of intracellular substances [<xref ref-type="bibr" rid="CR2">2</xref>], including synphilin-1, cyclin E, P38 tRNA synthetase, SP22 (22-kDa glycosylated form of α-synuclein), and more [<xref ref-type="bibr" rid="CR8">8</xref>] (Fig. <xref ref-type="fig" rid="Fig2">2</xref>a).<fig id="Fig2"><label>Fig. 2</label><caption><p>Function of Parkin. <bold>a</bold> Proteasome degradation pathway. <bold>b</bold> Pathway of PINK1 activation of Parkin leading to autophagy of depolarized mitochondria. <bold>c</bold> Degradation pathway of unfolded or misfolded proteins. <italic>ub</italic> ubiquitin, <italic>OMM</italic> outer mitochondrial membrane, <italic>P</italic> phosphorylation, <italic>CCCP</italic> carbonyl cyanide 3-chlorophenylhydrazone</p></caption><graphic id="MO2" xlink:href="40880_2019_421_Fig2_HTML"></graphic></fig>
</p>
</sec>
<sec id="Sec6">
<title>The role and mechanism of Parkin in mitochondrial autophagy</title>
<p id="Par38">Mitochondrial autophagy is a physiological process that removes damaged or excessive mitochondria through a degradation pathway in autophagosomes [<xref ref-type="bibr" rid="CR13">13</xref>]. The Parkin/PTEN-induced kinase 1 (PINK1) pathway is the most typical mitochondrial autophagy pathway [<xref ref-type="bibr" rid="CR14">14</xref>]. In damaged mitochondria, depolarization of the mitochondrial membrane results in the immobilization of PINK1 on the outer membrane of the mitochondria and activation by autophosphorylation [<xref ref-type="bibr" rid="CR15">15</xref>]. Activated PINK1 phosphorylates many substrates, including Parkin and ubiquitin, and experiments have shown that the combination between phospho-ubiquitination (p-Ub) and phosphorylated Parkin has a high affinity that causes Parkin to produce a conformational change. As a result, the recruitment of E2 is promoted, thus activating Parkin [<xref ref-type="bibr" rid="CR16">16</xref>]. Parkin rapidly catalyzes the ubiquitination of large amounts of mitochondrial proteins, followed by ubiquitinated mitochondrial proteomes linked to autophagic machinery and initiation of selective autophagy [<xref ref-type="bibr" rid="CR17">17</xref>] (Fig. <xref ref-type="fig" rid="Fig2">2</xref>b).</p>
<p id="Par39">In addition to PINK1/Parkin-mediated mitochondrial autophagy, autophagy-mediated by the B-cell lymphoma-2 (Bcl-2) and adenovirus E1B 19 kDa-interacting protein 3 (BNIP3) and NIP3-like protein X (NIX) signaling pathways also plays a key role in autophagy [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR19">19</xref>]. Studies have found that BNIP3 and NIX can directly link to the microtubule-associated protein light chain 3 (LC3) protein and recruit autophagosomes to degrade targeted proteins and NIX can also directly modulate ubiquitination of Parkin substrates to mediate mitochondrial autophagy [<xref ref-type="bibr" rid="CR19">19</xref>]. However, whether PINK1/Parkin-mediated mitochondrial autophagy pathway is associated with this pathway will be a new field for future studies of mitochondrial autophagy.</p>
</sec>
<sec id="Sec7">
<title>Parkin as an important monitoring system in the cell</title>
<p id="Par40">When intracellular proteins are misfolded, the ubiquitin–proteasome system can remove or degrade these proteins in time, thereby effectively reducing the cytotoxic load caused by excessive accumulation of misfolded proteins [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR7">7</xref>] (Fig. <xref ref-type="fig" rid="Fig2">2</xref>c). This mechanism has important protective effects on cells. When the endoplasmic reticulum undergoes a stress response, the protein is unfolded or misfolded, and Parkin’s E3 ubiquitin ligase activity is lost, resulting in the accumulation of a large number of mitochondrial proteins and many other substrates, and ultimately induces endoplasmic reticulum stress-mediated cell death [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR4">4</xref>]. For instance, regarding the Peal receptor protein, studies have confirmed that it has dopamine neurotoxicity, which can cause stress in endoplasmic reticulum and cytoplasm of the cell, thereby inducing dopaminergic neurons death in the substantia nigra of the brain [<xref ref-type="bibr" rid="CR20">20</xref>]. The inactivation of Parkin protein magnifies these damaging effects. Parkin proteins are dephosphorylated and more active when cells are exposed to stress caused by Parkinson’s disease-associated folding proteins [<xref ref-type="bibr" rid="CR21">21</xref>]. Phosphorylation and dephosphorylation of Parkin can rapidly and efficiently regulate its functions and activities when proteins are misfolded or threatened by cell survival.</p>
</sec>
</sec>
</sec>
<sec id="Sec8">
<title>Post-translational modification of Parkin</title>
<p id="Par41">Post-translational modification (PTM) is a fundamental process to regulate protein functions [<xref ref-type="bibr" rid="CR7">7</xref>]. Different types of modifications affect the conformation and stability of the protein and ultimately its function [<xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR23">23</xref>]. Phosphorylation, methylation, ubiquitination, acetylation, sumoylation, neddylation, glycosylation and sulfation are all common post-translational modifications of proteins (Table <xref ref-type="table" rid="Tab1">1</xref>). Parkin’s activity can be regulated by various types of PTM, for example, phosphorylation, ubiquitination, sumoylation and neddylation [<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR25">25</xref>]. These reversible PTMs cause Parkin to translocate, affecting its DNA binding affinity, and altering the transcriptional activity pattern of a particular target gene locus [<xref ref-type="bibr" rid="CR26">26</xref>]. When cells are subjected to environmental stress or signal stimulation, certain functions can be obtained or lost through specific post-translational modification, thereby producing specific effects [<xref ref-type="bibr" rid="CR27">27</xref>].<table-wrap id="Tab1"><label>Table 1</label><caption><p>The type of post-translational modification that Parkin participates in and its biological function</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Post-translational modification type</th><th align="left">Modification site</th><th align="left">Modification of related enzymes</th><th align="left">Biological functions</th></tr></thead><tbody><tr><td align="left">Phosphorylation</td><td align="left">Serine, threonine, tyrosine</td><td align="left">Protein kinase, protein phosphatase</td><td align="left">Signal transduction, cell cycle, growth and development, cancer mechanism</td></tr><tr><td align="left">Ubiquitination</td><td align="left">Lysine</td><td align="left">Ubiquitin activating enzyme, binding enzyme, ligase and degrading enzyme, ubiquitin-specific protease</td><td align="left">Cell proliferation, apoptosis, DNA damage repair, Immune response</td></tr><tr><td align="left">Sumoylation</td><td align="left">Lysine</td><td align="left">SUMO-specific protease</td><td align="left">Mitochondrial division, DNA damage repair, genomic stability</td></tr><tr><td align="left">Neddylation</td><td align="left">Lysine</td><td align="left">NEDD8 activating enzyme, Cullin E3 enzyme</td><td align="left">Cell cycle, signal transduction, apoptosis</td></tr><tr><td align="left">S-Nitrosylation</td><td align="left">Cysteine</td><td align="left">Nitric oxide synthase</td><td align="left">Apoptosis, inflammatory response, immunosuppression</td></tr></tbody></table></table-wrap>
</p>
<p id="Par42">Parkin’s post-translational modifications do not exist in isolation, but rather have intricate connections with each other, forming a complex post-translational modification control network. The phosphorylation of Parkin not only inhibits ubiquitination but also acetylation [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR28">28</xref>]. Therefore, Parkin may have some post-transcriptional modifications, and no interactions between various modifications have been detected. The importance of these modifications in specific tumorigenesis remains to be elucidated.</p>
<sec id="Sec9">
<title>Mechanism of Parkin activation by phosphorylation</title>
<p id="Par43">Different protein kinases can recognize and modify different sites of different proteins, which expands the complexity of phosphorylated protein research [<xref ref-type="bibr" rid="CR29">29</xref>]. The molecular mechanisms of protein phosphorylation have considerable guiding significance for the study of major diseases such as cancer and have become one of the hotspots in the field of biology. The primary mechanism for modulating Parkin activity and its target genes is to control Parkin’s translocation between the nucleus and cytoplasm by phosphorylation of a series of kinases [<xref ref-type="bibr" rid="CR30">30</xref>]. There are a variety of proteins involved in Parkin phosphorylation, of which PINK1 is the most studied protein [<xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR32">32</xref>]. Kim et al. reported that Parkin’s activity and mitochondrial localization depended on PINK1 kinase-activity [<xref ref-type="bibr" rid="CR32">32</xref>]. Two research reports [<xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR34">34</xref>] also indicated that Parkin translocation and stress-induced mitochondrial autophagy requires the PINK1-dependent phosphorylation of Ser65 in the UbL domain [<xref ref-type="bibr" rid="CR35">35</xref>]. The initiation of phosphor-ubiquitin makes Parkin easier to PINK1-mediated Ser65 phosphorylation [<xref ref-type="bibr" rid="CR36">36</xref>]. So, in a nutshell, the phosphorylation of PINK1 is necessary for Parkin activation and target recognition [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR36">36</xref>, <xref ref-type="bibr" rid="CR37">37</xref>].</p>
</sec>
<sec id="Sec10">
<title>Parkin’s ubiquitination and deubiquitination</title>
<p id="Par44">Protein ubiquitination is a fundamental post-translational modification that controls cell fate and function [<xref ref-type="bibr" rid="CR7">7</xref>]. It has been reported that Parkin mediates its own ubiquitination through K48 protein-dependent ubiquitin chain formation, thereby affecting the stability of its own proteins [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR38">38</xref>]. Durcan and colleagues identified the deubiquitinating enzyme (DUB) Ataxin-3 as a ligand for Parkin, which interacts with Parkin’s UbL and IBR-RING2 domains and promotes Parkin’s β-dimerization [<xref ref-type="bibr" rid="CR39">39</xref>]. Mutant Ataxin-3, a polyglutamine dilatation associated with the onset of Machado-Joseph neurodegenerative disease, promotes Parkin degradation by autophagy and leads to a decrease in Parkin levels in in vivo [<xref ref-type="bibr" rid="CR40">40</xref>]. In a subsequent study, it was shown that Ataxin-3 binds to the E2 ubiquitin ligase Ubc7 instead of Parkin and promotes Parkin de-ubiquitination only when Parkin itself is ubiquitinated [<xref ref-type="bibr" rid="CR41">41</xref>]. Collectively, these highlight the complex regulation of Parkin ubiquitination, involving the coordinated activities of Parkin, DUB and E2 ubiquitin ligase [<xref ref-type="bibr" rid="CR42">42</xref>, <xref ref-type="bibr" rid="CR43">43</xref>]. It is known that when Parkin is ubiquitinated in cells, it degrades in a proteasome-dependent manner, effectively inactivating Parkin [<xref ref-type="bibr" rid="CR44">44</xref>]. In conclusion, the ubiquitination process involved in Parkin protein plays a key role in protein localization and degradation [<xref ref-type="bibr" rid="CR45">45</xref>].</p>
</sec>
<sec id="Sec11">
<title>Sumoylation modification</title>
<p id="Par45">In recent years, many proteins similar to ubiquitin sequences have been discovered, one of which is the ubiquitin-related analogue SUMO (small ubiquitin-related modification) [<xref ref-type="bibr" rid="CR46">46</xref>]. SUMO is a highly conserved family of proteins widely found in eukaryotes. There are three SUMO genes in vertebrates called SUMO-1, -2, -3, which are very similar to ubiquitin in secondary structure and catalytically modified [<xref ref-type="bibr" rid="CR46">46</xref>, <xref ref-type="bibr" rid="CR47">47</xref>]. This modification plays an important role in stabilizing protein conformation and regulating protein subcellular localization [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR48">48</xref>]. Studies have shown that non-covalent binding of Parkin protein to SUMO-1 enhances Parkin’s nuclear translocation and increases its own ubiquitination, but no significant Parkin protein level difference was detected after the overexpression of SUMO-1, indicating that an increase in autoubiquitination activity does not necessarily result in the protease-dependent degradation of Parkin [<xref ref-type="bibr" rid="CR48">48</xref>]. Therefore, a positive regulator of Parkin, such as SUMO-1, may simply disintegrate the self-inhibiting conformation of Parkin protein or enhance the binding of E2 to the substrate without causing degradation of the Parkin protein [<xref ref-type="bibr" rid="CR49">49</xref>], thereby causing apoptosis of cancer cells. Recent studies have found that sumoylation is also involved in the repair of DNA damage and the regulation of mitochondrial division, genomic stability, ion channels, and biological rhythms. In addition, disorders of the SUMO-modifying function can cause certain diseases to occur [<xref ref-type="bibr" rid="CR49">49</xref>]. The function of many oncogenes and tumor suppressor genes is regulated by SUMO modification, such as P53, IRF-1 (interferon regulatory factor 1) [<xref ref-type="bibr" rid="CR46">46</xref>]. Studies have shown that SUMO1 modification can inhibit the activity of the P53 gene and promote the occurrence, development, and metastasis of cancer [<xref ref-type="bibr" rid="CR50">50</xref>, <xref ref-type="bibr" rid="CR51">51</xref>]. IRF-1 is a tumor suppressor and inhibits phenotypic changes. The SUMO modification level of IRF-1 was significantly increased in tumor cells by screening for SUMO protein. SUMO modification of IRF-1 increases the stability of this protein in tumors [<xref ref-type="bibr" rid="CR52">52</xref>].</p>
</sec>
<sec id="Sec12">
<title>Neddylation modification</title>
<p id="Par46">Neural precursor cell-expressed developmentally downregulated 8 (NEDD8) is a class of molecules with similar structure to ubiquitin proteins, called neddylation, which can be involved in the post-translational modification of proteins. Like ubiquitin, NEDD8 is also expressed in most tissue types [<xref ref-type="bibr" rid="CR53">53</xref>, <xref ref-type="bibr" rid="CR54">54</xref>]. Recent studies have shown that protein neddylation modification abnormalities are closely related to the occurrence and development of a variety of tumors [<xref ref-type="bibr" rid="CR55">55</xref>]. Enzymes involved in neddylation modification are higher in tumors than normal adjacent tissues. Neddylation modification has become a new anti-tumor therapeutic target that can exert its anti-tumor effect by ubiquitin ligase regulating the neddylation modification process [<xref ref-type="bibr" rid="CR55">55</xref>, <xref ref-type="bibr" rid="CR56">56</xref>]. Studies have shown that Parkin binds to the ubiquitin-like protein NEDD8 [<xref ref-type="bibr" rid="CR57">57</xref>], indicating that NEDD8 is linked to Parkin to increase E3 ligase activity by increasing the affinity to E2 ubiquitin ligase Ubiquitin-conjugating Enzyme H8 (UbcH8) and putative substrate aminoacyltransferase p38 subunit, thereby inhibiting the development of the tumor. Walden et al. reported that neddylation enhanced the interaction of Parkin with UbcH8 and its putative substrate, the p38 subunit of the amino acyltransferase, which enhances the activity of ubiquitin ligase [<xref ref-type="bibr" rid="CR11">11</xref>]. Nedd8 is capable of bidirectional regulation of ubiquitination. When Nedd8 modifies the Cullin E3 enzyme by neddylation, it changes its enzyme configuration, making E3 easier to bind to the E2 binding enzyme, and the ubiquitination-modifying enzyme activity of E3 is promoted [<xref ref-type="bibr" rid="CR53">53</xref>]. However, when neddylation competes with the ubiquitination modification for the same modification site, it can also inhibit the ubiquitination of the substrate. RING box proteins (RBXs), a component of the ubiquitin ligase Cullin-RING complex, is the most studied neddylation modified ligase, and further studies have found that ubiquitin ligases MDM2 (murine double minute 2), Smurf1 (Smad ubiquitin regulatory factor 1) and NEDL2 (NEDD4-like ubiquitin ligase 2) can also act as neddylation modified ligases [<xref ref-type="bibr" rid="CR7">7</xref>].</p>
</sec>
<sec id="Sec13">
<title>Parkin protein S-nitrosylation and cancers</title>
<p id="Par47">S-nitrosylation is a reversible post-translational modification involving the covalent attachment of a NO (nitric oxide) group to a cysteine residue to form an S-nitrosothiol species that stabilizes the structure of the protein [<xref ref-type="bibr" rid="CR58">58</xref>, <xref ref-type="bibr" rid="CR59">59</xref>]. Numerous studies have shown that abnormal S-nitrosylation is associated with the development and progression of cancer and the response to certain therapies [<xref ref-type="bibr" rid="CR58">58</xref>]. S-nitrosylation abnormalities are key events in cancer episodes and may significantly increase cancer risk [<xref ref-type="bibr" rid="CR60">60</xref>]. S-nitrosylation regulates the biological activities of a variety of proteins in the body and is involved in key processes in the cell life cycle, including transcriptional regulation, DNA repair and apoptosis [<xref ref-type="bibr" rid="CR58">58</xref>, <xref ref-type="bibr" rid="CR60">60</xref>]. Parkin is rich in cysteine and coordinates 8 zinc atoms to ensure proper folding of Parkin. Therefore, the S-nitrosylation of any zinc-coordinated cysteine affects Parkin’s function [<xref ref-type="bibr" rid="CR61">61</xref>]. However, it is controversial that S-nitrosylation regulating Parkin’s function. On one hand, the effect of S-nitrosylation on the mitochondrial degradation of Parkin function in human neuroblastoma cells (SH-SY5Y) by Ozawa group [<xref ref-type="bibr" rid="CR62">62</xref>] found that S-nitrosylation of Parkin protein increases E3 ligase activity after mitochondrial depolarization to induce mitochondrial aggregation and degradation, in addition, Cys323 in Parkin is S-nitrosylated key site. On the other hand, Ted Dawson’s team [<xref ref-type="bibr" rid="CR58">58</xref>] found that the degree of S-nitrosylation of parkin protein was increased in the human brain and the S-nitrosylation of Parkin protein attenuated E3 ligase activity after mitochondrial depolarization. In addition, studies have demonstrated that the functional regulation of Parkin protein S-nitrosylation is bidirectional and undergo self-ubiquitination. S-nitrosylation will increase first and then decrease [<xref ref-type="bibr" rid="CR58">58</xref>]. Therefore, the specific mechanism by which S-nitrosylation regulates Parkin’s function requires further study.</p>
</sec>
</sec>
<sec id="Sec14">
<title>Parkin’s relationship with cancer and its regulatory mechanism</title>
<sec id="Sec15">
<title>Tumor suppressor gene—Parkin</title>
<p id="Par48">There is increasing evidence that Parkin is a tumor suppressor, mutations in the <italic>Parkin</italic> gene have been reported in many cancers, although the frequency of these mutations is relatively low [<xref ref-type="bibr" rid="CR4">4</xref>]. Analyses of the database from cBioportal (<ext-link ext-link-type="uri" xlink:href="http://www.cbioportal.org">http://www.cbioportal.org</ext-link>) indicate that <italic>Parkin</italic> gene mutation rate is ~ 5% in cervical cancer, ~ 5% in lung squamous cell carcinoma, and 2%–6% in colorectal cancer [<xref ref-type="bibr" rid="CR63">63</xref>]. Studies have confirmed that Parkin’s deletion of the long arm of chromosome 6 is associated with several solid tumors, including ovarian cancer, breast cancer, kidney cancer, lung cancer, melanoma, and hematological cancer [<xref ref-type="bibr" rid="CR4">4</xref>]. A number of missing regions were identified by analysis of 6q21-q23, 6q25.1-q25.2, and 6q25-q27. In addition, a loss of 6q27 was found in benign ovarian tumors. Later studies identified a homozygous deletion of exon 2 in lung adenocarcinoma [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR64">64</xref>]. Parkin’s loss of heterozygosity and loss of copy number were observed in breast cancer [<xref ref-type="bibr" rid="CR65">65</xref>]. With in-depth studies on Parkin, it was found that its overexpression inhibits the proliferation of cancer cells, while Parkin’s inactivation promotes the proliferation of cancer cells, demonstrating that Parkin acts as a tumor suppressor [<xref ref-type="bibr" rid="CR63">63</xref>, <xref ref-type="bibr" rid="CR66">66</xref>]. Parkin gene deletions and mutations often occur in lung cancer, and the inactivation of the Parkin gene increases the incidence of lung cancer. By analyzing the cancer genome map, it was found that about one-quarter of the glioblastoma samples had heterozygous or homozygous loss of the Parkin gene and point mutation [<xref ref-type="bibr" rid="CR67">67</xref>]. Experiments have shown that mice lacking the <italic>Parkin</italic> gene are more prone to pancreatic cancer [<xref ref-type="bibr" rid="CR68">68</xref>]. The reduction of the <italic>Parkin</italic> gene enhances the proliferation and migration of pancreatic cancer cells. When the <italic>Parkin</italic> gene is overexpressed, the migration and invasion ability of cancer cells is weakened, indicating that Parkin has the potential to inhibit pancreatic cancer, and its expression level is positively correlated.</p>
</sec>
<sec id="Sec16">
<title>Parkin-mediated tumor suppression and underlying mechanisms</title>
<sec id="Sec17">
<title>Anti-apoptosis</title>
<p id="Par49">Apoptosis is the balance between multicellular organisms to maintain cell stability. The active physically death process of cells controlled by genes is a natural obstacle to the development of cancer [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR17">17</xref>]. Recent studies have found that Parkin seems to promote cancer cell apoptosis. Parkin has been reported to induce apoptosis by promoting mitochondrial depolarization [<xref ref-type="bibr" rid="CR69">69</xref>]. Parkin promotes the ubiquitination and degradation of myeloid cell leukemia-1 (Mcl-1), a member of the B-cell leukemia/lymphoma 2 (Bcl-2) family, and open the Bax/Bak channel, making cells sensitive to apoptosis [<xref ref-type="bibr" rid="CR69">69</xref>]. In the Michigan Cancer Foundation 7 (MCF7) human breast cancer cells, Parkin binds to the outer surface of microtubules to increase the interaction of paclitaxel with microtubules, increasing cell sensitivity to apoptosis [<xref ref-type="bibr" rid="CR70">70</xref>]. Parkin also promotes histone deacetylases (HDAC) inhibitors to induce apoptosis in hepatocellular carcinoma through a mechanism that is poorly understood. In conclusion, Parkin can promote cancer cell apoptosis through different pathways.</p>
</sec>
<sec id="Sec18">
<title>Anti-cell proliferation</title>
<p id="Par50">The ability to maintain chronic proliferative signals is the most important feature of cancer cell survival. Previous studies have shown that Parkin plays an important role in inhibiting cell cycle progression. Parkin regulates the stability of G1/S cyclins and maintains the coordination of different cyclins, thus acts as a major regulator of the cell cycle. Interestingly, Parkin’s loss is mutually exclusive with the amplification of cyclin D1, cyclin E1 [<xref ref-type="bibr" rid="CR60">60</xref>, <xref ref-type="bibr" rid="CR71">71</xref>] and cyclin-dependent kinase 4 (CDK4) genes, suggesting that Parkin and these cell cycle components interact in a common pathway [<xref ref-type="bibr" rid="CR72">72</xref>]. In MCF7 breast cancer cells, Parkin is reported to regulate the mRNA levels of CDK6 (cyclin-dependent kinase 6) [<xref ref-type="bibr" rid="CR11">11</xref>], which leads to cell cycle arrest and growth inhibition [<xref ref-type="bibr" rid="CR73">73</xref>]. Thus, Parkin mutation abolishes its ligase activity and impairs its ability to ubiquitinate cyclins, which in turn leads to amplification of G1/S [<xref ref-type="bibr" rid="CR72">72</xref>] phase cyclin turnover, hyperproliferative signaling and ultimately cancer [<xref ref-type="bibr" rid="CR74">74</xref>].</p>
</sec>
<sec id="Sec19">
<title>Anti-cell metastasis</title>
<p id="Par51">Tumor invasion and metastasis are the most critical steps in defining the aggressive phenotype of human cancer [<xref ref-type="bibr" rid="CR75">75</xref>]. As a potential tumor suppressor protein, the increased expression of Parkin may be related to the viability of invasion and metastasis. Parkin helps microtubule polymerization through its three separate microtubule/tubulin-binding domains and cooperates with paclitaxel treatment to increase their stability [<xref ref-type="bibr" rid="CR63">63</xref>]. In breast cancer, a decrease in Parkin’s cytoplasmic expression may be helpful in predicting paclitaxel treatment outcomes [<xref ref-type="bibr" rid="CR73">73</xref>]. In addition, it was found that when parkin is overexpressed, the migration and invasion ability of various cancer cells is weakened [<xref ref-type="bibr" rid="CR73">73</xref>]. Since microtubule dynamics are closely related to cell migration and metastasis, Parkin has some negative regulation on cancer cell metastasis through its microtubule-stabilizing activity [<xref ref-type="bibr" rid="CR76">76</xref>]. Collectively, these studies demonstrated the potential role of Parkin in the tumor microenvironment [<xref ref-type="bibr" rid="CR63">63</xref>].</p>
</sec>
<sec id="Sec20">
<title>Anti-angiogenesis</title>
<p id="Par52">Cancer cells require adequate nutrition and oxygen to maintain and assess the ability to metabolize waste. To achieve this, as early as 1971, American scholar Folkman put forward the theory that “tumor growth depends on angiogenesis” [<xref ref-type="bibr" rid="CR77">77</xref>]. Vascular endothelial growth factor (VEGF) is one of the most potent stimulating factors found in angiogenesis, affecting endothelial cell proliferation, motor and vascular permeability [<xref ref-type="bibr" rid="CR78">78</xref>, <xref ref-type="bibr" rid="CR79">79</xref>]. Interestingly, it was observed that Parkin significantly affected the expression of vascular endothelial growth factor receptor-2 (VEGFR-2). In U87-Parkin cells (Glioma cells stably expressing Parkin), the expression of VEGFR-2 was found to be nearly 4-fold lower than the control group [<xref ref-type="bibr" rid="CR11">11</xref>]. In most invasive tumors, the production and secretion of VEGF are usually observed, a phenomenon that seriously affects the prognosis of cancer patients [<xref ref-type="bibr" rid="CR80">80</xref>]. In a study of glioma cells, the negative relation between Parkin function and VEGFR-2 has been shown to be a key factor in promoting angiogenesis. Thus, Parkin-mediated inhibition of glioma cell proliferation involves the regulation of the VEGFR-2 pathway [<xref ref-type="bibr" rid="CR11">11</xref>].</p>
</sec>
<sec id="Sec21">
<title>Anti-inflammation</title>
<p id="Par53">How inflammation induces tumors is an important scientific issue in the international frontier. Previous studies have demonstrated that many tumors are induced by inflammation [<xref ref-type="bibr" rid="CR81">81</xref>]. Inflammatory mediators cause genetic and epigenetic changes such as DNA methylation, tumor suppressor gene point mutations, and post-translational modifications, which cause changes in intracellular homeostasis and occurrence of tumors [<xref ref-type="bibr" rid="CR81">81</xref>, <xref ref-type="bibr" rid="CR82">82</xref>]. With in-depth research, inflammatory mediators involved in the occurrence and development of tumors have been identified [<xref ref-type="bibr" rid="CR83">83</xref>]. The expression of inflammatory markers interleukin-1β (IL-1β) and tumor necrosis factor-α (TNF-α) was abnormally increased in Parkin-deficient cells [<xref ref-type="bibr" rid="CR84">84</xref>, <xref ref-type="bibr" rid="CR85">85</xref>], while IL-6 level was significantly higher in Parkin knocked-out mice than in wild-type [<xref ref-type="bibr" rid="CR67">67</xref>]. A recent study has suggested that inflammation and genomic instability caused by Parkin deficiency may be a trigger in lung cancer [<xref ref-type="bibr" rid="CR86">86</xref>]. In the absence of any stimulation, a decrease in Parkin expression leads to an increase in nuclear factor kappa B (NF-κB) localization [<xref ref-type="bibr" rid="CR67">67</xref>]. NF-κB is a widely expressed transcription factor that induces cytokine and immunoglobulin gene expression in chronic obstructive pulmonary disease-associated inflammation [<xref ref-type="bibr" rid="CR86">86</xref>]. These results proved that Parkin has anti-inflammatory properties, while Parkin deficiency may aggravate inflammation.</p>
</sec>
</sec>
</sec>
<sec id="Sec22">
<title>Conclusions and perspectives</title>
<p id="Par54">In recent years, evidence from cultured cells and Parkin knockout mice experiments, as well as clinical studies have shown that Parkin is an important tumor suppressor that is abnormally expressed in many malignancies, including colorectal cancer, lung cancer, and endometrial cancer [<xref ref-type="bibr" rid="CR7">7</xref>]. As a tumor suppressor gene, little is known about the way that parkin inhibits tumor growth, as well as the mechanisms of the parkin promoter region methylation and parkin mutation leading to tumorigenesis.</p>
<p id="Par55">The role of Parkin in Parkinson’s disease has been established, and the association between Parkinson’s disease and cancer risk seems complicated, and many epidemiological studies have shown a connection between Parkinson’s disease and the risk of developing gastric cancer, uterine cancer, lung cancer, and breast cancer [<xref ref-type="bibr" rid="CR87">87</xref>]. Previous studies have shown that the incidence of most cancer in Parkinson’s patients is lower than in patients without Parkinson’s disease [<xref ref-type="bibr" rid="CR55">55</xref>, <xref ref-type="bibr" rid="CR58">58</xref>]. In patients with Parkinson’s disease, the risk of smoking-related cancer is reduced, such as lung cancer, bladder cancer, and laryngeal cancer [<xref ref-type="bibr" rid="CR5">5</xref>]. However, the risk of malignant melanoma and breast cancer in patients with Parkinson’s disease has increased significantly [<xref ref-type="bibr" rid="CR55">55</xref>]. Therefore, future research should consider whether the risk of cancer in patients with Parkinson’s disease is higher than in patients with non-Parkinson’s disease, and the potential roles of Parkin mutations in regulating the relationship between Parkinson’s disease and cancer risk.</p>
<p id="Par56">Post-translational modifications can control the activity, conformation, solubility, and cofactor interactions required for Parkin activation, substrate affinity and specificity. When cells are subjected to environmental stress or changes in the internal environment, post-translational modifications can occur rapidly to regulate various activities of the cell. In recent years, researchers in many countries have been focusing on the role of Parkin as a tumor suppressor [<xref ref-type="bibr" rid="CR65">65</xref>]. However, little is known about post-translational modifications of Parkin participates in the development of tumors. Future research should explore the effects of post-translational modification on tumors and whether it can be used as a new approach to prevent tumorigenesis by regulating post-translational modification of Parkin.</p>
</sec>
</body>
<back>
<glossary>
<title>Abbreviations</title>
<def-list>
<def-item>
<term>AR-JP</term>
<def>
<p id="Par2">autosomal recessive juvenile parkinsonism</p>
</def>
</def-item>
<def-item>
<term>RBR</term>
<def>
<p id="Par3">RING1-IBR-RING2</p>
</def>
</def-item>
<def-item>
<term>UBL</term>
<def>
<p id="Par4">ubiquitin-like domain</p>
</def>
</def-item>
<def-item>
<term>UPS</term>
<def>
<p id="Par5">ubiquitin–proteasome system</p>
</def>
</def-item>
<def-item>
<term>SP22</term>
<def>
<p id="Par6">22-kilodalton glycosylated form of α-synuclein</p>
</def>
</def-item>
<def-item>
<term>PINK1</term>
<def>
<p id="Par7">PTEN-induced kinase 1</p>
</def>
</def-item>
<def-item>
<term>p-Ub</term>
<def>
<p id="Par8">phospho-ubiquitination</p>
</def>
</def-item>
<def-item>
<term>BNIP3</term>
<def>
<p id="Par9">Bcl-2 and adenovirus E1B19 kDa-interacting protein 3</p>
</def>
</def-item>
<def-item>
<term>NIX</term>
<def>
<p id="Par10">NIP3-like protein X</p>
</def>
</def-item>
<def-item>
<term>LC3</term>
<def>
<p id="Par11">microtubule-associated protein light chain 3</p>
</def>
</def-item>
<def-item>
<term>PTM</term>
<def>
<p id="Par12">post-translational modification</p>
</def>
</def-item>
<def-item>
<term>DUB</term>
<def>
<p id="Par13">deubiquitinating enzyme</p>
</def>
</def-item>
<def-item>
<term>SUMO</term>
<def>
<p id="Par14">small ubiquitin-related modifier</p>
</def>
</def-item>
<def-item>
<term>NEDD8</term>
<def>
<p id="Par15">neural precursor cell-expressed developmentally downregulated 8</p>
</def>
</def-item>
<def-item>
<term>RBXs</term>
<def>
<p id="Par16">RING box proteins</p>
</def>
</def-item>
<def-item>
<term>MDM2</term>
<def>
<p id="Par17">murine double minute 2</p>
</def>
</def-item>
<def-item>
<term>Smurf1</term>
<def>
<p id="Par18">mad ubiquitin regulatory factor 1</p>
</def>
</def-item>
<def-item>
<term>NEDL2</term>
<def>
<p id="Par19">NEDD4-like ubiquitin ligase 2</p>
</def>
</def-item>
<def-item>
<term>NO</term>
<def>
<p id="Par20">nitric oxide</p>
</def>
</def-item>
<def-item>
<term>Mcl-1</term>
<def>
<p id="Par21">myeloid cell leukemia-1</p>
</def>
</def-item>
<def-item>
<term>SH-SY5Y</term>
<def>
<p id="Par22">human neuroblastoma cells</p>
</def>
</def-item>
<def-item>
<term>MCF7</term>
<def>
<p id="Par23">Michigan Cancer Foundation 7</p>
</def>
</def-item>
<def-item>
<term>Bcl-2</term>
<def>
<p id="Par24">B-cell leukemia/lymphoma 2</p>
</def>
</def-item>
<def-item>
<term>HDAC</term>
<def>
<p id="Par25">histone deacetylases</p>
</def>
</def-item>
<def-item>
<term>CDK4</term>
<def>
<p id="Par26">cyclin-dependent kinase 4</p>
</def>
</def-item>
<def-item>
<term>CDK6</term>
<def>
<p id="Par27">cyclin-dependent kinase 6</p>
</def>
</def-item>
<def-item>
<term>VEGF</term>
<def>
<p id="Par28">vascular endothelial growth factor</p>
</def>
</def-item>
<def-item>
<term>VEGFR-2</term>
<def>
<p id="Par29">vascular endothelial growth factor receptor-2</p>
</def>
</def-item>
<def-item>
<term>IL-1β</term>
<def>
<p id="Par30">interleukin-1β</p>
</def>
</def-item>
<def-item>
<term>TNF-α</term>
<def>
<p id="Par31">tumor necrosis factor-α</p>
</def>
</def-item>
<def-item>
<term>NF-κB</term>
<def>
<p id="Par32">nuclear factor kappa B</p>
</def>
</def-item>
<def-item>
<term>Ig</term>
<def>
<p id="Par33">immunoglobulin</p>
</def>
</def-item>
<def-item>
<term>COPD</term>
<def>
<p id="Par34">chronic obstructive pulmonary disease</p>
</def>
</def-item>
</def-list>
</glossary>
<ack>
<title>Acknowledgements</title>
<p>Not applicable.</p>
</ack>
<notes notes-type="author-contribution">
<title>Authors’ contributions</title>
<p>DD and JW conceived the theme and structure of the article and wrote the manuscript. DD, XA, and YW edited figures, and DD, JW, XA, YL, YW, HF and MW edited and revised the article, JW, YH provided materials and funding. All authors read and approved the manuscript.</p>
</notes>
<notes notes-type="funding-information">
<title>Funding</title>
<p>This work was supported by the National Natural Science Foundation of China (81622005), and Beijing Natural Science Foundation (7172213).</p>
</notes>
<notes notes-type="data-availability">
<title>Availability of data and materials</title>
<p>Not applicable.</p>
</notes>
<notes>
<title>Ethics approval and consent to participate</title>
<p id="Par57">Not applicable.</p>
</notes>
<notes>
<title>Consent for publication</title>
<p id="Par58">Not applicable.</p>
</notes>
<notes notes-type="COI-statement">
<title>Competing interests</title>
<p id="Par59">The authors declare that they have no competing interests.</p>
</notes>
<ref-list id="Bib1">
<title>References</title>
<ref id="CR1">
<label>1.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kitada</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Asakawa</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Hattori</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Matsumine</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Yamamura</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Minoshima</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism</article-title>
<source/>Nature
          <year>1998</year>
<volume>392</volume>
<issue>6676</issue>
<fpage>605</fpage>
<pub-id pub-id-type="doi">10.1038/33416</pub-id>
<pub-id pub-id-type="pmid">9560156</pub-id>
</element-citation>
</ref>
<ref id="CR2">
<label>2.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stichel</surname>
<given-names>CC</given-names>
</name>
<name>
<surname>Augustin</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kühn</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>XR</given-names>
</name>
<name>
<surname>Engels</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Ullmer</surname>
<given-names>C</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Parkin expression in the adult mouse brain</article-title>
<source/>Eur J Neurosci
          <year>2000</year>
<volume>12</volume>
<issue>12</issue>
<fpage>4181</fpage>
<pub-id pub-id-type="doi">10.1046/j.1460-9568.2000.01314.x</pub-id>
<pub-id pub-id-type="pmid">11122330</pub-id>
</element-citation>
</ref>
<ref id="CR3">
<label>3.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Seirafi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kozlov</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Gehring</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>Parkin structure and function</article-title>
<source/>FEBS J.
          <year>2015</year>
<volume>282</volume>
<issue>11</issue>
<fpage>2076</fpage>
<lpage>2088</lpage>
<pub-id pub-id-type="doi">10.1111/febs.13249</pub-id>
<pub-id pub-id-type="pmid">25712550</pub-id>
</element-citation>
</ref>
<ref id="CR4">
<label>4.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cesari</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Martin</surname>
<given-names>ES</given-names>
</name>
<name>
<surname>Calin</surname>
<given-names>GA</given-names>
</name>
<name>
<surname>Pentimalli</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Bichi</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Mcadams</surname>
<given-names>H</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Parkin, a gene implicated in autosomal recessive juvenile parkinsonism, is a candidate tumor suppressor gene on chromosome 6q25-q27</article-title>
<source/>Proc Natl Acad Sci USA
          <year>2003</year>
<volume>100</volume>
<issue>10</issue>
<fpage>5956</fpage>
<pub-id pub-id-type="doi">10.1073/pnas.0931262100</pub-id>
<pub-id pub-id-type="pmid">12719539</pub-id>
</element-citation>
</ref>
<ref id="CR5">
<label>5.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Feng</surname>
<given-names>Z</given-names>
</name>
</person-group>
<article-title>Parkinson’s disease-associated protein Parkin: an unusual player in cancer</article-title>
<source/>Cancer Commun
          <year>2018</year>
<volume>38</volume>
<issue>1</issue>
<fpage>40</fpage>
<pub-id pub-id-type="doi">10.1186/s40880-018-0314-z</pub-id>
</element-citation>
</ref>
<ref id="CR6">
<label>6.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xiang</surname>
<given-names>RL</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Cong</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>ZJ</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>LL</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Type 2 diabetes-induced hyposalivation of the submandibular gland through PINK1/Parkin-mediated mitophagy</article-title>
<source/>J Cell Physiol
          <year>2020</year>
<volume>235</volume>
<issue>1</issue>
<fpage>232</fpage>
<lpage>244</lpage>
<pub-id pub-id-type="doi">10.1002/jcp.28962</pub-id>
<pub-id pub-id-type="pmid">31190343</pub-id>
</element-citation>
</ref>
<ref id="CR7">
<label>7.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chakraborty</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Basso</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Ziviani</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>Post translational modification of Parkin</article-title>
<source/>Biol Direct.
          <year>2017</year>
<volume>12</volume>
<issue>1</issue>
<fpage>6</fpage>
<pub-id pub-id-type="doi">10.1186/s13062-017-0176-3</pub-id>
<pub-id pub-id-type="pmid">28222786</pub-id>
</element-citation>
</ref>
<ref id="CR8">
<label>8.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Dawson</surname>
<given-names>VL</given-names>
</name>
<name>
<surname>Dawson</surname>
<given-names>TM</given-names>
</name>
</person-group>
<article-title>Parkin functions as an E2-dependent ubiquitin-protein ligase and promotes the degradation of the synaptic vesicle-associated protein, CDCrel-1</article-title>
<source/>Proc Natl Acad Sci USA
          <year>2000</year>
<volume>97</volume>
<issue>24</issue>
<fpage>13354</fpage>
<lpage>13359</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.240347797</pub-id>
<pub-id pub-id-type="pmid">11078524</pub-id>
</element-citation>
</ref>
<ref id="CR9">
<label>9.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zarate-Lagunes</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Gu</surname>
<given-names>WJ</given-names>
</name>
<name>
<surname>Blanchard</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Francois</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Muriel</surname>
<given-names>MP</given-names>
</name>
<name>
<surname>Mouatt-Prigent</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Parkin immunoreactivity in the brain of human and non-human primates: an immunohistochemical analysis in normal conditions and in Parkinsonian syndromes</article-title>
<source/>J Comp Neurol
          <year>2001</year>
<volume>432</volume>
<issue>2</issue>
<fpage>184</fpage>
<lpage>196</lpage>
<pub-id pub-id-type="doi">10.1002/cne.1096</pub-id>
<pub-id pub-id-type="pmid">11241385</pub-id>
</element-citation>
</ref>
<ref id="CR10">
<label>10.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shridhar</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Staub</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Huntley</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Cliby</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Jenkins</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Pass</surname>
<given-names>HI</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A novel region of deletion on chromosome 6q23.3 spanning less than 500 Kb in high grade invasive epithelial ovarian cancer</article-title>
<source/>Oncogene.
          <year>1999</year>
<volume>18</volume>
<issue>26</issue>
<fpage>3913</fpage>
<pub-id pub-id-type="doi">10.1038/sj.onc.1202756</pub-id>
<pub-id pub-id-type="pmid">10445856</pub-id>
</element-citation>
</ref>
<ref id="CR11">
<label>11.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yeo</surname>
<given-names>CW</given-names>
</name>
<name>
<surname>Ng</surname>
<given-names>FS</given-names>
</name>
<name>
<surname>Chai</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Tan</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Koh</surname>
<given-names>GR</given-names>
</name>
<name>
<surname>Chong</surname>
<given-names>YK</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Parkin pathway activation mitigates glioma cell proliferation and predicts patient survival</article-title>
<source/>Can Res
          <year>2012</year>
<volume>72</volume>
<issue>10</issue>
<fpage>2543</fpage>
<pub-id pub-id-type="doi">10.1158/0008-5472.CAN-11-3060</pub-id>
</element-citation>
</ref>
<ref id="CR12">
<label>12.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Randow</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Youle</surname>
<given-names>RJ</given-names>
</name>
</person-group>
<article-title>Self and nonself: how autophagy targets mitochondria and bacteria</article-title>
<source/>Cell Host Microbe
          <year>2014</year>
<volume>15</volume>
<issue>4</issue>
<fpage>403</fpage>
<lpage>411</lpage>
<pub-id pub-id-type="doi">10.1016/j.chom.2014.03.012</pub-id>
<pub-id pub-id-type="pmid">24721569</pub-id>
</element-citation>
</ref>
<ref id="CR13">
<label>13.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yorimitsu</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Klionsky</surname>
<given-names>DJ</given-names>
</name>
</person-group>
<article-title>Autophagy: molecular machinery for self-eating</article-title>
<source/>Cell Death Differ
          <year>2005</year>
<volume>2</volume>
<issue>12 Suppl</issue>
<fpage>1542</fpage>
<lpage>1552</lpage>
<pub-id pub-id-type="doi">10.1038/sj.cdd.4401765</pub-id>
</element-citation>
</ref>
<ref id="CR14">
<label>14.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vivesbauza</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Cui</surname>
<given-names>M</given-names>
</name>
<name>
<surname>de Vries</surname>
<given-names>RL</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<article-title>PINK1-dependent recruitment of Parkin to mitochondria in mitophagy</article-title>
<source/>Proc Natl Acad Sci USA
          <year>2010</year>
<volume>107</volume>
<issue>2</issue>
<fpage>378</fpage>
<lpage>383</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.0911187107</pub-id>
<pub-id pub-id-type="pmid">19966284</pub-id>
</element-citation>
</ref>
<ref id="CR15">
<label>15.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Seok Min</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Youle</surname>
<given-names>RJ</given-names>
</name>
</person-group>
<article-title>PINK1- and Parkin-mediated mitophagy at a glance</article-title>
<source/>J Cell Sci
          <year>2012</year>
<volume>125</volume>
<issue>4</issue>
<fpage>795</fpage>
<lpage>799</lpage>
<pub-id pub-id-type="doi">10.1242/jcs.093849</pub-id>
<pub-id pub-id-type="pmid">22448035</pub-id>
</element-citation>
</ref>
<ref id="CR16">
<label>16.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kahori</surname>
<given-names>SF</given-names>
</name>
<name>
<surname>Tsuyoshi</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Nobutaka</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Yuzuru</surname>
<given-names>I</given-names>
</name>
</person-group>
<article-title>PINK1-mediated phosphorylation of Parkin boosts Parkin activity in Drosophila</article-title>
<source/>PLoS Genet
          <year>2014</year>
<volume>10</volume>
<issue>6</issue>
<fpage>e1004391</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pgen.1004391</pub-id>
<pub-id pub-id-type="pmid">24901221</pub-id>
</element-citation>
</ref>
<ref id="CR17">
<label>17.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hang</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Thundyil</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Lim</surname>
<given-names>KL</given-names>
</name>
</person-group>
<article-title>Mitochondrial dysfunction and Parkinson disease: a Parkin-AMPK alliance in neuroprotection</article-title>
<source/>Ann N Y Acad Sci
          <year>2015</year>
<volume>1350</volume>
<issue>1</issue>
<fpage>37</fpage>
<lpage>47</lpage>
<pub-id pub-id-type="doi">10.1111/nyas.12820</pub-id>
<pub-id pub-id-type="pmid">26121488</pub-id>
</element-citation>
</ref>
<ref id="CR18">
<label>18.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fatima Zahra</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Stéphanie</surname>
<given-names>SP</given-names>
</name>
<name>
<surname>Jaclyn Nicole</surname>
<given-names>LG</given-names>
</name>
<name>
<surname>Annick</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Régis</surname>
<given-names>DM</given-names>
</name>
<name>
<surname>Gilles</surname>
<given-names>D</given-names>
</name>
<etal></etal>
</person-group>
<article-title>GABARAPL1 (GEC1) associates with autophagic vesicles</article-title>
<source/>Autophagy.
          <year>2010</year>
<volume>6</volume>
<issue>4</issue>
<fpage>495</fpage>
<lpage>505</lpage>
<pub-id pub-id-type="doi">10.4161/auto.6.4.11819</pub-id>
<pub-id pub-id-type="pmid">20404487</pub-id>
</element-citation>
</ref>
<ref id="CR19">
<label>19.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Youngil</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Hwa-Youn</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Hanna</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Gustafsson</surname>
<given-names>ÅB</given-names>
</name>
</person-group>
<article-title>Mitochondrial autophagy by Bnip3 involves Drp1-mediated mitochondrial fission and recruitment of Parkin in cardiac myocytes</article-title>
<source/>Am J Physiol Heart Circ Physiol.
          <year>2011</year>
<volume>301</volume>
<issue>5</issue>
<fpage>1924</fpage>
<lpage>1931</lpage>
<pub-id pub-id-type="doi">10.1152/ajpheart.00368.2011</pub-id>
</element-citation>
</ref>
<ref id="CR20">
<label>20.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yasuko</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Yuzuru</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Kentaro</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Ayane</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Toshio</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Mariko</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Pael receptor induces death of dopaminergic neurons in the substantia nigra via endoplasmic reticulum stress and dopamine toxicity, which is enhanced under condition of parkin inactivation</article-title>
<source/>Hum Mol Genet.
          <year>2007</year>
<pub-id pub-id-type="doi">10.1093/hmg/ddl439</pub-id>
</element-citation>
</ref>
<ref id="CR21">
<label>21.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ayako</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Arno</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Yuzuru</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Ryosuke</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Kahle</surname>
<given-names>PJ</given-names>
</name>
<name>
<surname>Christian</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Parkin phosphorylation and modulation of its E3 ubiquitin ligase activity</article-title>
<source/>J Biol Chem
          <year>2005</year>
<volume>280</volume>
<issue>5</issue>
<fpage>3390</fpage>
<pub-id pub-id-type="doi">10.1074/jbc.M407724200</pub-id>
<pub-id pub-id-type="pmid">15557340</pub-id>
</element-citation>
</ref>
<ref id="CR22">
<label>22.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Berndsen</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Wolberger</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>New insights into ubiquitin E3 ligase mechanism</article-title>
<source/>Nat Struct Mol Biol
          <year>2014</year>
<volume>21</volume>
<issue>4</issue>
<fpage>301</fpage>
<lpage>307</lpage>
<pub-id pub-id-type="doi">10.1038/nsmb.2780</pub-id>
<pub-id pub-id-type="pmid">24699078</pub-id>
</element-citation>
</ref>
<ref id="CR23">
<label>23.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Ao</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Ding</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Ponnusamy</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Hao</surname>
<given-names>X</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Critical role of FOXO3a in carcinogenesis</article-title>
<source/>Mol Cancer.
          <year>2018</year>
<pub-id pub-id-type="doi">10.1186/s12943-018-0856-3</pub-id>
<pub-id pub-id-type="pmid">30572883</pub-id>
</element-citation>
</ref>
<ref id="CR24">
<label>24.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>L</given-names>
</name>
</person-group>
<article-title>Phosphorylation and acetylation modifications of FOXO3a: independently or synergistically?</article-title>
<source/>Oncol Lett
          <year>2017</year>
<volume>13</volume>
<issue>5</issue>
<fpage>2867</fpage>
<lpage>2872</lpage>
<pub-id pub-id-type="doi">10.3892/ol.2017.5851</pub-id>
<pub-id pub-id-type="pmid">28521392</pub-id>
</element-citation>
</ref>
<ref id="CR25">
<label>25.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sanphui</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Biswas</surname>
<given-names>SC</given-names>
</name>
</person-group>
<article-title>FoxO3a is activated and executes neuron death via Bim in response to β-amyloid</article-title>
<source/>Cell Death Dis
          <year>2013</year>
<volume>4</volume>
<issue>5</issue>
<fpage>e625</fpage>
<pub-id pub-id-type="doi">10.1038/cddis.2013.148</pub-id>
<pub-id pub-id-type="pmid">23661003</pub-id>
</element-citation>
</ref>
<ref id="CR26">
<label>26.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Daitoku</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Sakamaki</surname>
<given-names>JI</given-names>
</name>
<name>
<surname>Fukamizu</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Regulation of FoxO transcription factors by acetylation and protein–protein interactions</article-title>
<source/>Biochim Biophys Acta
          <year>2011</year>
<volume>1813</volume>
<issue>11</issue>
<fpage>1954</fpage>
<lpage>1960</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbamcr.2011.03.001</pub-id>
<pub-id pub-id-type="pmid">21396404</pub-id>
</element-citation>
</ref>
<ref id="CR27">
<label>27.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>XJ</given-names>
</name>
</person-group>
<article-title>Multisite protein modification and intramolecular signaling</article-title>
<source/>Oncogene
          <year>2005</year>
<volume>24</volume>
<issue>10</issue>
<fpage>1653</fpage>
<lpage>1662</lpage>
<pub-id pub-id-type="doi">10.1038/sj.onc.1208173</pub-id>
<pub-id pub-id-type="pmid">15744326</pub-id>
</element-citation>
</ref>
<ref id="CR28">
<label>28.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gupta</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Anjomani-Virmouni</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Koundouros</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Dimitriadi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Choo-Wing</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Valle</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>PARK2 depletion connects energy and oxidative stress to PI3K/Akt activation via PTEN S-nitrosylation</article-title>
<source/>Mol Cell
          <year>2017</year>
<volume>65</volume>
<issue>6</issue>
<fpage>999</fpage>
<pub-id pub-id-type="doi">10.1016/j.molcel.2017.02.019</pub-id>
<pub-id pub-id-type="pmid">28306514</pub-id>
</element-citation>
</ref>
<ref id="CR29">
<label>29.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Avraham</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Rott</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Liani</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Szargel</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Engelender</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Phosphorylation of Parkin by the cyclin-dependent kinase 5 at the linker region modulates its ubiquitin-ligase activity and aggregation</article-title>
<source/>J Biol Chem
          <year>2007</year>
<volume>282</volume>
<issue>17</issue>
<fpage>12842</fpage>
<pub-id pub-id-type="doi">10.1074/jbc.M608243200</pub-id>
<pub-id pub-id-type="pmid">17327227</pub-id>
</element-citation>
</ref>
<ref id="CR30">
<label>30.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Finnberg</surname>
<given-names>N</given-names>
</name>
<name>
<surname>El-Deiry</surname>
<given-names>WS</given-names>
</name>
</person-group>
<article-title>Activating FOXO3a, NF-kappaB and p53 by targeting IKKs: an effective multi-faceted targeting of the tumor-cell phenotype?</article-title>
<source/>Cancer Biol Ther
          <year>2004</year>
<volume>3</volume>
<issue>7</issue>
<fpage>614</fpage>
<lpage>616</lpage>
<pub-id pub-id-type="doi">10.4161/cbt.3.7.1057</pub-id>
<pub-id pub-id-type="pmid">15254408</pub-id>
</element-citation>
</ref>
<ref id="CR31">
<label>31.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sha</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Chin</surname>
<given-names>LS</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>L</given-names>
</name>
</person-group>
<article-title>Phosphorylation of parkin by Parkinson disease-linked kinase PINK1 activates parkin E3 ligase function and NF-κB signaling</article-title>
<source/>Hum Mol Genet
          <year>2010</year>
<volume>19</volume>
<issue>2</issue>
<fpage>352</fpage>
<lpage>363</lpage>
<pub-id pub-id-type="doi">10.1093/hmg/ddp501</pub-id>
<pub-id pub-id-type="pmid">19880420</pub-id>
</element-citation>
</ref>
<ref id="CR32">
<label>32.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kim</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kwon</surname>
<given-names>SK</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>SH</given-names>
</name>
<etal></etal>
</person-group>
<article-title>PINK1 controls mitochondrial localization of Parkin through direct phosphorylation</article-title>
<source/>Biochem Biophys Res Commun
          <year>2008</year>
<volume>377</volume>
<issue>3</issue>
<fpage>975</fpage>
<lpage>980</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbrc.2008.10.104</pub-id>
<pub-id pub-id-type="pmid">18957282</pub-id>
</element-citation>
</ref>
<ref id="CR33">
<label>33.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kondapalli</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Kazlauskaite</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Woodroof</surname>
<given-names>HI</given-names>
</name>
<name>
<surname>Campbell</surname>
<given-names>DG</given-names>
</name>
<name>
<surname>Gourlay</surname>
<given-names>R</given-names>
</name>
<etal></etal>
</person-group>
<article-title>PINK1 is activated by mitochondrial membrane potential depolarization and stimulates Parkin E3 ligase activity by phosphorylating Serine 65</article-title>
<source/>Open Biol
          <year>2012</year>
<volume>2</volume>
<issue>5</issue>
<fpage>120080</fpage>
<pub-id pub-id-type="doi">10.1098/rsob.120080</pub-id>
<pub-id pub-id-type="pmid">22724072</pub-id>
</element-citation>
</ref>
<ref id="CR34">
<label>34.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shiba-Fukushima</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Imai</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Yoshida</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Ishihama</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Kanao</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Sato</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>PINK1-mediated phosphorylation of the Parkin ubiquitin-like domain primes mitochondrial translocation of Parkin and regulates mitophagy</article-title>
<source/>Sci Rep
          <year>2012</year>
<volume>2</volume>
<issue>12</issue>
<fpage>1002</fpage>
<pub-id pub-id-type="doi">10.1038/srep01002</pub-id>
<pub-id pub-id-type="pmid">23256036</pub-id>
</element-citation>
</ref>
<ref id="CR35">
<label>35.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Poole</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Thomas</surname>
<given-names>RE</given-names>
</name>
<name>
<surname>Andrews</surname>
<given-names>LA</given-names>
</name>
<name>
<surname>Mcbride</surname>
<given-names>HM</given-names>
</name>
<name>
<surname>Whitworth</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Pallanck</surname>
<given-names>LJ</given-names>
</name>
</person-group>
<article-title>The PINK1/Parkin pathway regulates mitochondrial morphology</article-title>
<source/>Proc Natl Acad Sci USA
          <year>2008</year>
<volume>105</volume>
<issue>5</issue>
<fpage>1638</fpage>
<lpage>1643</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.0709336105</pub-id>
<pub-id pub-id-type="pmid">18230723</pub-id>
</element-citation>
</ref>
<ref id="CR36">
<label>36.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kazlauskaite</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Martínez-Torres</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>Wilkie</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kumar</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Peltier</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Gonzalez</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Binding to serine 65-phosphorylated ubiquitin primes Parkin for optimal PINK1-dependent phosphorylation and activation</article-title>
<source/>EMBO Rep
          <year>2015</year>
<volume>16</volume>
<issue>8</issue>
<fpage>939</fpage>
<lpage>954</lpage>
<pub-id pub-id-type="doi">10.15252/embr.201540352</pub-id>
<pub-id pub-id-type="pmid">26116755</pub-id>
</element-citation>
</ref>
<ref id="CR37">
<label>37.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Ii</surname>
<given-names>GWD</given-names>
</name>
</person-group>
<article-title>PINK1-phosphorylated mitofusin 2 is a Parkin receptor for culling damaged mitochondria</article-title>
<source/>Science
          <year>2013</year>
<volume>340</volume>
<issue>6131</issue>
<fpage>471</fpage>
<lpage>475</lpage>
<pub-id pub-id-type="doi">10.1126/science.1231031</pub-id>
<pub-id pub-id-type="pmid">23620051</pub-id>
</element-citation>
</ref>
<ref id="CR38">
<label>38.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pinto</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Pedro</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Costa</surname>
<given-names>RO</given-names>
</name>
<name>
<surname>Almeida</surname>
<given-names>RD</given-names>
</name>
</person-group>
<article-title>Visualizing K48 ubiquitination during presynaptic formation by ubiquitination-induced fluorescence complementation (UiFC)</article-title>
<source/>Front Mol Neurosci
          <year>2016</year>
<volume>9</volume>
<fpage>43</fpage>
<pub-id pub-id-type="doi">10.3389/fnmol.2016.00043</pub-id>
<pub-id pub-id-type="pmid">27375430</pub-id>
</element-citation>
</ref>
<ref id="CR39">
<label>39.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Durcan</surname>
<given-names>TM</given-names>
</name>
<name>
<surname>Fon</surname>
<given-names>EA</given-names>
</name>
</person-group>
<article-title>Mutant ataxin-3 promotes the autophagic degradation of parkin</article-title>
<source/>Autophagy.
          <year>2011</year>
<volume>7</volume>
<issue>2</issue>
<fpage>233</fpage>
<lpage>234</lpage>
<pub-id pub-id-type="doi">10.4161/auto.7.2.14224</pub-id>
<pub-id pub-id-type="pmid">21116127</pub-id>
</element-citation>
</ref>
<ref id="CR40">
<label>40.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Durcan</surname>
<given-names>TM</given-names>
</name>
<name>
<surname>Kontogiannea</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Thorarinsdottir</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Fallon</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Williams</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Djarmati</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The Machado-Joseph disease-associated mutant form of ataxin-3 regulates parkin ubiquitination and stability</article-title>
<source/>Hum Mol Genet
          <year>2011</year>
<volume>20</volume>
<issue>1</issue>
<fpage>141</fpage>
<pub-id pub-id-type="doi">10.1093/hmg/ddq452</pub-id>
<pub-id pub-id-type="pmid">20940148</pub-id>
</element-citation>
</ref>
<ref id="CR41">
<label>41.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Durcan</surname>
<given-names>TM</given-names>
</name>
<name>
<surname>Kontogiannea</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Bedard</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Wing</surname>
<given-names>SS</given-names>
</name>
<name>
<surname>Fon</surname>
<given-names>EA</given-names>
</name>
</person-group>
<article-title>Ataxin-3 deubiquitination is coupled to Parkin ubiquitination via E2 ubiquitin-conjugating enzyme</article-title>
<source/>J Biol Chem
          <year>2012</year>
<volume>287</volume>
<issue>1</issue>
<fpage>531</fpage>
<lpage>541</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M111.288449</pub-id>
<pub-id pub-id-type="pmid">22081612</pub-id>
</element-citation>
</ref>
<ref id="CR42">
<label>42.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Varshavsky</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>The ubiquitin system</article-title>
<source/>Nat Med
          <year>1998</year>
<volume>67</volume>
<issue>67</issue>
<fpage>1</fpage>
<lpage>17</lpage>
<pub-id pub-id-type="doi">10.1146/annurev.biochem.67.1.425</pub-id>
</element-citation>
</ref>
<ref id="CR43">
<label>43.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hegde</surname>
<given-names>AN</given-names>
</name>
</person-group>
<article-title>The ubiquitin-proteasome pathway and synaptic plasticity</article-title>
<source/>Learn Mem
          <year>2010</year>
<volume>17</volume>
<issue>7</issue>
<fpage>314</fpage>
<pub-id pub-id-type="doi">10.1101/lm.1504010</pub-id>
<pub-id pub-id-type="pmid">20566674</pub-id>
</element-citation>
</ref>
<ref id="CR44">
<label>44.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Federica</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Mark</surname>
<given-names>VDM</given-names>
</name>
<name>
<surname>Suzan</surname>
<given-names>VDL</given-names>
</name>
<name>
<surname>Domenico</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>Oxidation of the cysteine-rich regions of parkin perturbs its E3 ligase activity and contributes to protein aggregation</article-title>
<source/>Mol Neurodegener
          <year>2011</year>
<volume>6</volume>
<issue>1</issue>
<fpage>34</fpage>
<pub-id pub-id-type="doi">10.1186/1750-1326-6-34</pub-id>
<pub-id pub-id-type="pmid">21595948</pub-id>
</element-citation>
</ref>
<ref id="CR45">
<label>45.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nagy</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Dikic</surname>
<given-names>I</given-names>
</name>
</person-group>
<article-title>Ubiquitin ligase complexes: from substrate selectivity to conjugational specificity</article-title>
<source/>Biol Chem
          <year>2010</year>
<volume>391</volume>
<issue>2/3</issue>
<fpage>163</fpage>
<lpage>169</lpage>
<pub-id pub-id-type="doi">10.1515/bc.2010.021</pub-id>
<pub-id pub-id-type="pmid">20030582</pub-id>
</element-citation>
</ref>
<ref id="CR46">
<label>46.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Müller</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Hoege</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Pyrowolakis</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Jentsch</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>SUMO, ubiquitin’s mysterious cousin</article-title>
<source/>Nat Rev Mol Cell Biol
          <year>2001</year>
<volume>2</volume>
<issue>3</issue>
<fpage>202</fpage>
<lpage>210</lpage>
<pub-id pub-id-type="doi">10.1038/35056591</pub-id>
<pub-id pub-id-type="pmid">11265250</pub-id>
</element-citation>
</ref>
<ref id="CR47">
<label>47.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hay</surname>
<given-names>RT</given-names>
</name>
</person-group>
<article-title>Protein modification by SUMO</article-title>
<source/>Trends Biochem Sci
          <year>2001</year>
<volume>26</volume>
<issue>5</issue>
<fpage>332</fpage>
<lpage>333</lpage>
<pub-id pub-id-type="doi">10.1016/S0968-0004(01)01849-7</pub-id>
<pub-id pub-id-type="pmid">11343927</pub-id>
</element-citation>
</ref>
<ref id="CR48">
<label>48.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Won</surname>
<given-names>UJ</given-names>
</name>
<name>
<surname>Kwang Chul</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>Functional modulation of parkin through physical interaction with SUMO-1</article-title>
<source/>J Neurosci Res
          <year>2010</year>
<volume>84</volume>
<issue>7</issue>
<fpage>1543</fpage>
<lpage>1554</lpage>
<pub-id pub-id-type="doi">10.1002/jnr.21041</pub-id>
</element-citation>
</ref>
<ref id="CR49">
<label>49.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guerra de Souza</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Prediger</surname>
<given-names>RD</given-names>
</name>
<name>
<surname>Cimarosti</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>SUMO-regulated mitochondrial function in Parkinson’s disease</article-title>
<source/>J Neurochem
          <year>2016</year>
<volume>137</volume>
<issue>5</issue>
<fpage>673</fpage>
<lpage>686</lpage>
<pub-id pub-id-type="doi">10.1111/jnc.13599</pub-id>
<pub-id pub-id-type="pmid">26932327</pub-id>
</element-citation>
</ref>
<ref id="CR50">
<label>50.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Watson</surname>
<given-names>IR</given-names>
</name>
<name>
<surname>Irwin</surname>
<given-names>MS</given-names>
</name>
</person-group>
<article-title>Ubiquitin and ubiquitin-like modifications of the p53 family</article-title>
<source/>Neoplasia.
          <year>2006</year>
<volume>8</volume>
<issue>8</issue>
<fpage>655</fpage>
<lpage>666</lpage>
<pub-id pub-id-type="doi">10.1593/neo.06439</pub-id>
<pub-id pub-id-type="pmid">16925948</pub-id>
</element-citation>
</ref>
<ref id="CR51">
<label>51.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bartosz</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Alicja</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Maura</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Ted</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Maciej</surname>
<given-names>Z</given-names>
</name>
</person-group>
<article-title>MDM2 chaperones the p53 tumor suppressor</article-title>
<source/>J Biol Chem
          <year>2007</year>
<volume>282</volume>
<issue>45</issue>
<fpage>32603</fpage>
<lpage>32612</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M702767200</pub-id>
<pub-id pub-id-type="pmid">17848574</pub-id>
</element-citation>
</ref>
<ref id="CR52">
<label>52.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Junsoo</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Kwangsoo</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Eun-Ju</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Yun-Jee</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Si-Nae</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Kyoungsook</surname>
<given-names>P</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Elevated level of SUMOylated IRF-1 in tumor cells interferes with IRF-1-mediated apoptosis</article-title>
<source/>Proc Natl Acad Sci USA
          <year>2007</year>
<volume>104</volume>
<issue>43</issue>
<fpage>17028</fpage>
<lpage>17033</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.0609852104</pub-id>
<pub-id pub-id-type="pmid">17942705</pub-id>
</element-citation>
</ref>
<ref id="CR53">
<label>53.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dil</surname>
<given-names>KA</given-names>
</name>
<name>
<surname>Kito</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Abe</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Shin</surname>
<given-names>RW</given-names>
</name>
<name>
<surname>Kamitani</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Ueda</surname>
<given-names>N</given-names>
</name>
</person-group>
<article-title>NEDD8 protein is involved in ubiquitinated inclusion bodies</article-title>
<source/>J Pathol
          <year>2003</year>
<volume>199</volume>
<issue>2</issue>
<fpage>259</fpage>
<lpage>266</lpage>
<pub-id pub-id-type="doi">10.1002/path.1283</pub-id>
<pub-id pub-id-type="pmid">12533840</pub-id>
</element-citation>
</ref>
<ref id="CR54">
<label>54.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ji</surname>
<given-names>WU</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>KA</given-names>
</name>
<name>
<surname>Im</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Oh</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Chung</surname>
<given-names>KC</given-names>
</name>
</person-group>
<article-title>Neddylation positively regulates the ubiquitin E3 ligase activity of parkin</article-title>
<source/>J Neurosci Res
          <year>2012</year>
<volume>90</volume>
<issue>5</issue>
<fpage>1030</fpage>
<lpage>1042</lpage>
<pub-id pub-id-type="doi">10.1002/jnr.22828</pub-id>
<pub-id pub-id-type="pmid">22271254</pub-id>
</element-citation>
</ref>
<ref id="CR55">
<label>55.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Soucy</surname>
<given-names>TA</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>PG</given-names>
</name>
<name>
<surname>Milhollen</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Berger</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Gavin</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Sharmila</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer</article-title>
<source/>Nature
          <year>2009</year>
<volume>458</volume>
<issue>7239</issue>
<fpage>732</fpage>
<lpage>736</lpage>
<pub-id pub-id-type="doi">10.1038/nature07884</pub-id>
<pub-id pub-id-type="pmid">19360080</pub-id>
</element-citation>
</ref>
<ref id="CR56">
<label>56.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yongchao</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Morgan</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Yi</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Targeting neddylation pathways to inactivate cullin-RING ligases for anticancer therapy</article-title>
<source/>Antioxid Redox Signal
          <year>2014</year>
<volume>21</volume>
<issue>17</issue>
<fpage>2383</fpage>
<lpage>2400</lpage>
<pub-id pub-id-type="doi">10.1089/ars.2013.5795</pub-id>
<pub-id pub-id-type="pmid">24410571</pub-id>
</element-citation>
</ref>
<ref id="CR57">
<label>57.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Choo</surname>
<given-names>YS</given-names>
</name>
<name>
<surname>Vogler</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Kalvakuri</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Iliuk</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Tao</surname>
<given-names>WA</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Regulation of parkin and PINK1 by neddylation</article-title>
<source/>Hum Mol Genet
          <year>2012</year>
<volume>21</volume>
<issue>11</issue>
<fpage>2514</fpage>
<lpage>2523</lpage>
<pub-id pub-id-type="doi">10.1093/hmg/dds070</pub-id>
<pub-id pub-id-type="pmid">22388932</pub-id>
</element-citation>
</ref>
<ref id="CR58">
<label>58.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chung</surname>
<given-names>KK</given-names>
</name>
<name>
<surname>Thomas</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Pletnikova</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Troncoso</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Marsh</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Dawson</surname>
<given-names>VL</given-names>
</name>
<etal></etal>
</person-group>
<article-title>S-nitrosylation of Parkin regulates ubiquitination and compromises Parkin’s protective function</article-title>
<source/>Science
          <year>2004</year>
<volume>304</volume>
<issue>5675</issue>
<fpage>1328</fpage>
<lpage>1331</lpage>
<pub-id pub-id-type="doi">10.1126/science.1093891</pub-id>
<pub-id pub-id-type="pmid">15105460</pub-id>
</element-citation>
</ref>
<ref id="CR59">
<label>59.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cho</surname>
<given-names>DH</given-names>
</name>
<name>
<surname>Nakamura</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Fang</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Cieplak</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Godzik</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Gu</surname>
<given-names>Z</given-names>
</name>
<etal></etal>
</person-group>
<article-title>S-nitrosylation of Drp1 mediates β-amyloid-related mitochondrial fission and neuronal injury</article-title>
<source/>Science
          <year>2009</year>
<volume>324</volume>
<issue>5923</issue>
<fpage>102</fpage>
<lpage>105</lpage>
<pub-id pub-id-type="doi">10.1126/science.1171091</pub-id>
<pub-id pub-id-type="pmid">19342591</pub-id>
</element-citation>
</ref>
<ref id="CR60">
<label>60.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Selvaraju</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Taylor</surname>
<given-names>BS</given-names>
</name>
<name>
<surname>Shasha</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Fang</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Emrullah</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Igor</surname>
<given-names>V</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Somatic mutations of the Parkinson’s disease-associated gene PARK2 in glioblastoma and other human malignancies</article-title>
<source/>Nat Genet
          <year>2010</year>
<volume>42</volume>
<issue>1</issue>
<fpage>77</fpage>
<lpage>82</lpage>
<pub-id pub-id-type="doi">10.1038/ng.491</pub-id>
<pub-id pub-id-type="pmid">19946270</pub-id>
</element-citation>
</ref>
<ref id="CR61">
<label>61.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hristova</surname>
<given-names>VA</given-names>
</name>
<name>
<surname>Beasley</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Rylett</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>Shaw</surname>
<given-names>GS</given-names>
</name>
</person-group>
<article-title>Identification of a novel Zn<sup>2+</sup>-binding domain in the autosomal recessive juvenile Parkinson-related E3 ligase parkin</article-title>
<source/>J Biol Chem
          <year>2009</year>
<volume>284</volume>
<issue>22</issue>
<fpage>14978</fpage>
<pub-id pub-id-type="doi">10.1074/jbc.m808700200</pub-id>
<pub-id pub-id-type="pmid">19339245</pub-id>
</element-citation>
</ref>
<ref id="CR62">
<label>62.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ozawa</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Komatsubara</surname>
<given-names>AT</given-names>
</name>
<name>
<surname>Nishimura</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Sawada</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Kawafune</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Tsumoto</surname>
<given-names>H</given-names>
</name>
<etal></etal>
</person-group>
<article-title>S-nitrosylation regulates mitochondrial quality control via activation of parkin</article-title>
<source/>Sci Rep
          <year>2013</year>
<volume>3</volume>
<issue>29</issue>
<fpage>2202</fpage>
<pub-id pub-id-type="doi">10.1038/srep02202</pub-id>
<pub-id pub-id-type="pmid">23857542</pub-id>
</element-citation>
</ref>
<ref id="CR63">
<label>63.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wahabi</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Perwez</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Rizvi</surname>
<given-names>MA</given-names>
</name>
</person-group>
<article-title>Parkin in Parkinson’s disease and cancer: a double-edged sword</article-title>
<source/>Mol Neurobiol
          <year>2018</year>
<volume>55</volume>
<issue>8</issue>
<fpage>6788</fpage>
<lpage>6800</lpage>
<pub-id pub-id-type="doi">10.1007/s12035-018-0879-1</pub-id>
<pub-id pub-id-type="pmid">29349575</pub-id>
</element-citation>
</ref>
<ref id="CR64">
<label>64.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Denison</surname>
<given-names>SR</given-names>
</name>
<name>
<surname>Fang</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Becker</surname>
<given-names>NA</given-names>
</name>
<name>
<surname>Birgitt</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Norman</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Phillips</surname>
<given-names>LA</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Alterations in the common fragile site gene Parkin in ovarian and other cancers</article-title>
<source/>Oncogene
          <year>2003</year>
<volume>22</volume>
<issue>51</issue>
<fpage>8370</fpage>
<pub-id pub-id-type="doi">10.1038/sj.onc.1207072</pub-id>
<pub-id pub-id-type="pmid">14614460</pub-id>
</element-citation>
</ref>
<ref id="CR65">
<label>65.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Yue</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Parkin targets HIF-1alpha for ubiquitination and degradation to inhibit breast tumor progression</article-title>
<source/>Nat Commun
          <year>2017</year>
<volume>8</volume>
<issue>1</issue>
<fpage>1823</fpage>
<pub-id pub-id-type="doi">10.1038/s41467-017-01947-w</pub-id>
<pub-id pub-id-type="pmid">29180628</pub-id>
</element-citation>
</ref>
<ref id="CR66">
<label>66.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stichel</surname>
<given-names>CC</given-names>
</name>
<name>
<surname>Augustin</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kühn</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>XR</given-names>
</name>
<name>
<surname>Engels</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Ullmer</surname>
<given-names>C</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Parkin expression in the adult mouse brain</article-title>
<source/>Eur J Neurosci
          <year>2010</year>
<volume>12</volume>
<issue>12</issue>
<fpage>4181</fpage>
<lpage>4194</lpage>
</element-citation>
</ref>
<ref id="CR67">
<label>67.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>SB</given-names>
</name>
<name>
<surname>She</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Bo</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Andrade</surname>
<given-names>MD</given-names>
</name>
<name>
<surname>Jie</surname>
<given-names>N</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Multiple-level validation identifies PARK2 in the development of lung cancer and chronic obstructive pulmonary disease</article-title>
<source/>Oncotarget.
          <year>2016</year>
<volume>7</volume>
<issue>28</issue>
<fpage>44211</fpage>
<lpage>44223</lpage>
<pub-id pub-id-type="doi">10.18632/oncotarget.9954</pub-id>
<pub-id pub-id-type="pmid">27329585</pub-id>
</element-citation>
</ref>
<ref id="CR68">
<label>68.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xiaodong</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Min</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Jihui</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Dengwen</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Youguang</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Xiuchao</surname>
<given-names>W</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Parkin deficiency contributes to pancreatic tumorigenesis by inducing spindle multipolarity and misorientation</article-title>
<source/>Cell Cycle
          <year>2013</year>
<volume>12</volume>
<issue>7</issue>
<fpage>1133</fpage>
<lpage>1141</lpage>
<pub-id pub-id-type="doi">10.4161/cc.24215</pub-id>
<pub-id pub-id-type="pmid">23470638</pub-id>
</element-citation>
</ref>
<ref id="CR69">
<label>69.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Carroll</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Hollville</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Martin</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Parkin sensitizes toward apoptosis induced by mitochondrial depolarization through promoting degradation of Mcl-1</article-title>
<source/>Cell Rep
          <year>2014</year>
<volume>9</volume>
<issue>4</issue>
<fpage>1538</fpage>
<lpage>1553</lpage>
<pub-id pub-id-type="doi">10.1016/j.celrep.2014.10.046</pub-id>
<pub-id pub-id-type="pmid">25456142</pub-id>
</element-citation>
</ref>
<ref id="CR70">
<label>70.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Peng</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Gu</surname>
<given-names>F</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Parkin regulates paclitaxel sensitivity in breast cancer via a microtubule-dependent mechanism</article-title>
<source/>J Pathol
          <year>2010</year>
<volume>218</volume>
<issue>1</issue>
<fpage>76</fpage>
<lpage>85</lpage>
<pub-id pub-id-type="doi">10.1002/path.2512</pub-id>
</element-citation>
</ref>
<ref id="CR71">
<label>71.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ikeuchi</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Hfujiwara</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Attenuation of proteolysis-mediated cyclin E regulation by alternatively spliced Parkin in human colorectal cancers</article-title>
<source/>Int J Cancer
          <year>2010</year>
<volume>125</volume>
<issue>9</issue>
<fpage>2029</fpage>
<lpage>2035</lpage>
<pub-id pub-id-type="doi">10.1002/ijc.24565</pub-id>
</element-citation>
</ref>
<ref id="CR72">
<label>72.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>He</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Niu</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Zhong</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Dan</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y</given-names>
</name>
<etal></etal>
</person-group>
<article-title>HMG-box transcription factor 1: a positive regulator of the G1/S transition through the Cyclin-CDK-CDKI molecular network in nasopharyngeal carcinoma</article-title>
<source/>Cell Death Dis
          <year>2018</year>
<volume>9</volume>
<issue>2</issue>
<fpage>100</fpage>
<pub-id pub-id-type="doi">10.1038/s41419-017-0175-4</pub-id>
<pub-id pub-id-type="pmid">29367693</pub-id>
</element-citation>
</ref>
<ref id="CR73">
<label>73.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tay</surname>
<given-names>SP</given-names>
</name>
<name>
<surname>Yeo</surname>
<given-names>CC</given-names>
</name>
<name>
<surname>Chua</surname>
<given-names>PJ</given-names>
</name>
<name>
<surname>Tan</surname>
<given-names>HM</given-names>
</name>
<name>
<surname>Ang</surname>
<given-names>AX</given-names>
</name>
<name>
<surname>Yip</surname>
<given-names>DL</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Parkin enhances the expression of cyclin-dependent kinase 6 and negatively regulates the proliferation of breast cancer cells</article-title>
<source/>J Biol Chem
          <year>2010</year>
<volume>285</volume>
<issue>38</issue>
<fpage>29231</fpage>
<pub-id pub-id-type="doi">10.1074/jbc.M110.108241</pub-id>
<pub-id pub-id-type="pmid">20630868</pub-id>
</element-citation>
</ref>
<ref id="CR74">
<label>74.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>SB</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>JJ</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Parkin regulates mitosis and genomic stability through Cdc20/Cdh1</article-title>
<source/>Mol Cell.
          <year>2015</year>
<volume>60</volume>
<issue>1</issue>
<fpage>21</fpage>
<lpage>34</lpage>
<pub-id pub-id-type="doi">10.1016/j.molcel.2015.08.011</pub-id>
<pub-id pub-id-type="pmid">26387737</pub-id>
</element-citation>
</ref>
<ref id="CR75">
<label>75.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Steeg</surname>
<given-names>PS</given-names>
</name>
</person-group>
<article-title>Metastasis suppressors alter the signal transduction of cancer cells</article-title>
<source/>Nat Rev Cancer
          <year>2003</year>
<volume>3</volume>
<issue>1</issue>
<fpage>55</fpage>
<pub-id pub-id-type="doi">10.1038/nrc967</pub-id>
<pub-id pub-id-type="pmid">12509767</pub-id>
</element-citation>
</ref>
<ref id="CR76">
<label>76.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kaverina</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Straube</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Regulation of cell migration by dynamic microtubules</article-title>
<source/>Semin Cell Dev Biol
          <year>2011</year>
<volume>22</volume>
<issue>9</issue>
<fpage>968</fpage>
<lpage>974</lpage>
<pub-id pub-id-type="doi">10.1016/j.semcdb.2011.09.017</pub-id>
<pub-id pub-id-type="pmid">22001384</pub-id>
</element-citation>
</ref>
<ref id="CR77">
<label>77.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ferlay</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Shin</surname>
<given-names>HR</given-names>
</name>
<name>
<surname>Bray</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Forman</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Mathers</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Parkin</surname>
<given-names>DM</given-names>
</name>
</person-group>
<article-title>Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008</article-title>
<source/>Int J Cancer
          <year>2010</year>
<pub-id pub-id-type="doi">10.1002/ijc.25516</pub-id>
<pub-id pub-id-type="pmid">21351270</pub-id>
</element-citation>
</ref>
<ref id="CR78">
<label>78.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Folkman</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Tumor angiogenesis: therapeutic implications</article-title>
<source/>N Engl J Med
          <year>1971</year>
<volume>285</volume>
<issue>21</issue>
<fpage>1182</fpage>
<pub-id pub-id-type="doi">10.1056/NEJM197111182852108</pub-id>
<pub-id pub-id-type="pmid">4938153</pub-id>
</element-citation>
</ref>
<ref id="CR79">
<label>79.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rs</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Ba</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>The anti-angiogenic basis of metronomic chemotherapy</article-title>
<source/>Nat Rev Cancer
          <year>2004</year>
<volume>4</volume>
<issue>6</issue>
<fpage>423</fpage>
<pub-id pub-id-type="doi">10.1038/nrc1369</pub-id>
<pub-id pub-id-type="pmid">15170445</pub-id>
</element-citation>
</ref>
<ref id="CR80">
<label>80.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Alitalo</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Carmeliet</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>Molecular mechanisms of lymphangiogenesis in health and disease</article-title>
<source/>Cancer Cell.
          <year>2002</year>
<volume>1</volume>
<issue>3</issue>
<fpage>219</fpage>
<lpage>227</lpage>
<pub-id pub-id-type="doi">10.1016/s1535-6108(02)00051-x</pub-id>
<pub-id pub-id-type="pmid">12086857</pub-id>
</element-citation>
</ref>
<ref id="CR81">
<label>81.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Philip</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Rowley</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Schreiber</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Inflammation as a tumor promoter in cancer induction</article-title>
<source/>Semin Cancer Biol
          <year>2004</year>
<volume>14</volume>
<issue>6</issue>
<fpage>433</fpage>
<lpage>439</lpage>
<pub-id pub-id-type="doi">10.1016/j.semcancer.2004.06.006</pub-id>
<pub-id pub-id-type="pmid">15489136</pub-id>
</element-citation>
</ref>
<ref id="CR82">
<label>82.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mitsutoshi</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Hiroki</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Hideki</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Takashi</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Wade</surname>
<given-names>PA</given-names>
</name>
<name>
<surname>Eling</surname>
<given-names>TE</given-names>
</name>
</person-group>
<article-title>DNA methylation-mediated silencing of nonsteroidal anti-inflammatory drug-activated gene (NAG-1/GDF15) in glioma cell lines</article-title>
<source/>Int J Cancer
          <year>2011</year>
<volume>130</volume>
<issue>2</issue>
<fpage>267</fpage>
<lpage>277</lpage>
<pub-id pub-id-type="doi">10.1002/ijc.26082</pub-id>
<pub-id pub-id-type="pmid">21437897</pub-id>
</element-citation>
</ref>
<ref id="CR83">
<label>83.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hussain</surname>
<given-names>SP</given-names>
</name>
<name>
<surname>Harris</surname>
<given-names>CC</given-names>
</name>
</person-group>
<article-title>Inflammation and cancer: an ancient link with novel potentials</article-title>
<source/>Int J Cancer
          <year>2010</year>
<volume>121</volume>
<issue>11</issue>
<fpage>2373</fpage>
<lpage>2380</lpage>
<pub-id pub-id-type="doi">10.1002/ijc.23173</pub-id>
</element-citation>
</ref>
<ref id="CR84">
<label>84.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Danesh</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Kaptoge</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Mann</surname>
<given-names>AG</given-names>
</name>
<name>
<surname>Sarwar</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Wood</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Angleman</surname>
<given-names>SB</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Long-term interleukin-6 levels and subsequent risk of coronary heart disease: two new prospective studies and a systematic review</article-title>
<source/>PLoS Med
          <year>2008</year>
<volume>5</volume>
<issue>4</issue>
<fpage>e78</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pmed.0050078</pub-id>
<pub-id pub-id-type="pmid">18399716</pub-id>
</element-citation>
</ref>
<ref id="CR85">
<label>85.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Popa</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Netea</surname>
<given-names>MG</given-names>
</name>
<name>
<surname>van Riel</surname>
<given-names>PL</given-names>
</name>
<name>
<surname>Jw</surname>
<given-names>VDM</given-names>
</name>
<name>
<surname>Stalenhoef</surname>
<given-names>AF</given-names>
</name>
</person-group>
<article-title>The role of TNF-alpha in chronic inflammatory conditions, intermediary metabolism, and cardiovascular risk</article-title>
<source/>J Lipid Res
          <year>2007</year>
<volume>48</volume>
<issue>4</issue>
<fpage>751</fpage>
<lpage>762</lpage>
<pub-id pub-id-type="doi">10.1194/jlr.R600021-JLR200</pub-id>
<pub-id pub-id-type="pmid">17202130</pub-id>
</element-citation>
</ref>
<ref id="CR86">
<label>86.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rom</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Avezov</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Aizenbud</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Reznick</surname>
<given-names>AZ</given-names>
</name>
</person-group>
<article-title>Cigarette smoking and inflammation revisited</article-title>
<source/>Respir Physiol Neurobiol
          <year>2013</year>
<volume>187</volume>
<issue>1</issue>
<fpage>5</fpage>
<lpage>10</lpage>
<pub-id pub-id-type="doi">10.1016/j.resp.2013.01.013</pub-id>
<pub-id pub-id-type="pmid">23376061</pub-id>
</element-citation>
</ref>
<ref id="CR87">
<label>87.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Freedman</surname>
<given-names>DM</given-names>
</name>
<name>
<surname>Pfeiffer</surname>
<given-names>RM</given-names>
</name>
</person-group>
<article-title>Factors in association between parkinson disease and risk of cancer in Taiwan</article-title>
<source/>JAMA Oncol
          <year>2016</year>
<volume>2</volume>
<issue>1</issue>
<fpage>144</fpage>
<pub-id pub-id-type="doi">10.1001/jamaoncol.2015.4151</pub-id>
<pub-id pub-id-type="pmid">26767558</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>